Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (12): 1177-1182.DOI: 10.3969/j.issn.1673-8640.2025.12.007
ZHAO Yilin, XU Yan, YIN Hui
Received:2024-07-26
Revised:2025-04-18
Online:2025-12-30
Published:2025-12-26
CLC Number:
ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p,miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma[J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.12.007
| 基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
|---|---|---|
| miR-145-5p | CTGATCCGACCGACATGCAG | GGCACTGATCGTGCCATGC |
| miR-200C-3p | CAACGCAATGCTGAATCGTAC | CACTGACGCTCAGCTACATG |
| miR-1290 | CATATGTCAGTGCTCATCGAC | CCATGATGCAATGCCTGCATGC |
| U6 | CCGTGACTGACAGTCACTGAC | GCTGAAGTCGATACGTAGG |
| 基因名称 | 上游引物(5'~3') | 下游引物(5'~3') |
|---|---|---|
| miR-145-5p | CTGATCCGACCGACATGCAG | GGCACTGATCGTGCCATGC |
| miR-200C-3p | CAACGCAATGCTGAATCGTAC | CACTGACGCTCAGCTACATG |
| miR-1290 | CATATGTCAGTGCTCATCGAC | CCATGATGCAATGCCTGCATGC |
| U6 | CCGTGACTGACAGTCACTGAC | GCTGAAGTCGATACGTAGG |
| 组别 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|
| 正常对照组 | 94 | 1.01±0.24 | 1.01±0.22 | 1.02±0.23 |
| 良性结节组 | 91 | 0.86±0.18* | 1.32±0.38* | 1.35±0.39* |
| PTC组 | 93 | 0.68±0.16*# | 1.65±0.45*# | 1.74±0.55*# |
| F值 | 66.022 | 72.894 | 71.899 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|
| 正常对照组 | 94 | 1.01±0.24 | 1.01±0.22 | 1.02±0.23 |
| 良性结节组 | 91 | 0.86±0.18* | 1.32±0.38* | 1.35±0.39* |
| PTC组 | 93 | 0.68±0.16*# | 1.65±0.45*# | 1.74±0.55*# |
| F值 | 66.022 | 72.894 | 71.899 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 项目 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 | 项目 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|---|---|---|---|---|
| 性别 | TNM分期 | ||||||||
| 男性 | 28 | 0.66±0.16 | 1.69±0.48 | 1.70±0.55 | Ⅰ~Ⅱ期 | 38 | 0.73±0.20 | 1.55±0.46 | 1.63±0.50 |
| 女性 | 65 | 0.69±0.18 | 1.63±0.40 | 1.76±0.58 | Ⅲ~Ⅳ期 | 55 | 0.65±0.19 | 1.72±0.49 | 1.82±0.58 |
| t值 | 0.761 | 0.624 | 0.465 | t值 | 1.954 | 1.686 | 1.641 | ||
| P值 | 0.448 | 0.534 | 0.643 | P值 | 0.054 | 0.095 | 0.104 | ||
| 年龄 | 血管间隙浸润 | ||||||||
| <45岁 | 34 | 0.70±0.16 | 1.59±0.42 | 1.68±0.54 | 无 | 36 | 0.72±0.19 | 1.57±0.42 | 1.60±0.51 |
| ≥45岁 | 59 | 0.67±0.18 | 1.68±0.45 | 1.77±0.57 | 有 | 57 | 0.65±0.17 | 1.70±0.48 | 1.83±0.59 |
| t值 | 0.805 | 0.951 | 0.747 | t值 | 1.848 | 1.334 | 1.927 | ||
| P值 | 0.423 | 0.344 | 0.457 | P值 | 0.068 | 0.186 | 0.057 | ||
| 肿瘤最大直径 | 淋巴转移 | ||||||||
| <3 cm | 31 | 0.69±0.19 | 1.62±0.44 | 1.69±0.51 | 无 | 46 | 0.82±0.20 | 1.35±0.34 | 1.39±0.36 |
| ≥3 cm | 62 | 0.68±0.17 | 1.67±0.46 | 1.77±0.58 | 有 | 47 | 0.54±0.15 | 1.94±0.51 | 2.08±0.62 |
| t值 | 0.257 | 0.501 | 0.652 | t值 | 7.649 | 6.550 | 6.545 | ||
| P值 | 0.798 | 0.617 | 0.516 | P值 | <0.001 | <0.001 | <0.001 |
| 项目 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 | 项目 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|---|---|---|---|---|
| 性别 | TNM分期 | ||||||||
| 男性 | 28 | 0.66±0.16 | 1.69±0.48 | 1.70±0.55 | Ⅰ~Ⅱ期 | 38 | 0.73±0.20 | 1.55±0.46 | 1.63±0.50 |
| 女性 | 65 | 0.69±0.18 | 1.63±0.40 | 1.76±0.58 | Ⅲ~Ⅳ期 | 55 | 0.65±0.19 | 1.72±0.49 | 1.82±0.58 |
| t值 | 0.761 | 0.624 | 0.465 | t值 | 1.954 | 1.686 | 1.641 | ||
| P值 | 0.448 | 0.534 | 0.643 | P值 | 0.054 | 0.095 | 0.104 | ||
| 年龄 | 血管间隙浸润 | ||||||||
| <45岁 | 34 | 0.70±0.16 | 1.59±0.42 | 1.68±0.54 | 无 | 36 | 0.72±0.19 | 1.57±0.42 | 1.60±0.51 |
| ≥45岁 | 59 | 0.67±0.18 | 1.68±0.45 | 1.77±0.57 | 有 | 57 | 0.65±0.17 | 1.70±0.48 | 1.83±0.59 |
| t值 | 0.805 | 0.951 | 0.747 | t值 | 1.848 | 1.334 | 1.927 | ||
| P值 | 0.423 | 0.344 | 0.457 | P值 | 0.068 | 0.186 | 0.057 | ||
| 肿瘤最大直径 | 淋巴转移 | ||||||||
| <3 cm | 31 | 0.69±0.19 | 1.62±0.44 | 1.69±0.51 | 无 | 46 | 0.82±0.20 | 1.35±0.34 | 1.39±0.36 |
| ≥3 cm | 62 | 0.68±0.17 | 1.67±0.46 | 1.77±0.58 | 有 | 47 | 0.54±0.15 | 1.94±0.51 | 2.08±0.62 |
| t值 | 0.257 | 0.501 | 0.652 | t值 | 7.649 | 6.550 | 6.545 | ||
| P值 | 0.798 | 0.617 | 0.516 | P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|
| 未复发组 | 73 | 0.75±0.17 | 1.46±0.38 | 1.53±0.41 |
| 复发组 | 20 | 0.42±0.10 | 2.34±0.52 | 2.51±0.57 |
| t值 | 8.277 | 8.439 | 8.664 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | miR-145-5p | miR-200C-3p | miR-1290 |
|---|---|---|---|---|
| 未复发组 | 73 | 0.75±0.17 | 1.46±0.38 | 1.53±0.41 |
| 复发组 | 20 | 0.42±0.10 | 2.34±0.52 | 2.51±0.57 |
| t值 | 8.277 | 8.439 | 8.664 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| miR-145-5p | 0.805(0.684~0.926) | 0.614 | 85.6 | 72.7 | 0.583 |
| miR-200C-3p | 0.842(0.751~0.932) | 1.863 | 80.6 | 80.9 | 0.615 |
| miR-1290 | 0.861(0.773~0.948) | 1.874 | 80.4 | 82.2 | 0.626 |
| 联合检测 | 0.942(0.870~0.999) | 0.912 | 85.0 | 97.3 | 0.823 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| miR-145-5p | 0.805(0.684~0.926) | 0.614 | 85.6 | 72.7 | 0.583 |
| miR-200C-3p | 0.842(0.751~0.932) | 1.863 | 80.6 | 80.9 | 0.615 |
| miR-1290 | 0.861(0.773~0.948) | 1.874 | 80.4 | 82.2 | 0.626 |
| 联合检测 | 0.942(0.870~0.999) | 0.912 | 85.0 | 97.3 | 0.823 |
| [1] | SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. |
| [2] |
宋晓龙, 秦晋铝, 杨茹, 等. 血清胸苷激酶1在甲状腺乳头状癌患者术后监测中的价值[J]. 检验医学, 2024, 39(2):155-160.
DOI |
| [3] | 曹文源, 罗晓婷, 何倩. 外泌体miRNA在甲状腺癌淋巴结转移临床诊断中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5):434-438. |
| [4] |
MASTRONIKOLIS N, TSIAMBAS E, ROUKAS D, et al. Micro-RNAs signatures in papillary thyroid carcinoma[J]. J BUON, 2020, 25(5):2144-2146.
PMID |
| [5] |
FENG J, ZHOU Q, YI H, et al. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3[J]. Cell Death Dis, 2019, 10(6):433.
DOI PMID |
| [6] |
FENG Y L, KE T, WANG G L, et al. MicroRNA-200c-3p negatively regulates ATP2A2 and promotes the progression of papillary thyroid carcinoma[J]. Biochem Genet, 2022, 60(5):1676-1694.
DOI |
| [7] |
KANG E, JUNG S C, NAM S K, et al. Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer[J]. Sci Rep, 2022, 12(1):2295.
DOI PMID |
| [8] | 中华医学会内分泌学分会,《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南—甲状腺疾病的实验室及辅助检查[J]. 中华内科杂志, 2007, 46(8):697-702. |
| [9] | PETRINI I, CECCHINI R L, MASCARÓ M, et al. Papillary thyroid carcinoma:a thorough bioinformatic analysis of gene expression and clinical data[J]. Genes(Basel), 2023, 14(6):1250. |
| [10] | FONSECA L, BORGES DUARTE D, BRANDÃO J R, et al. Papillary thyroid carcinoma:the impact of histologic vascular invasion[J]. Minerva Endocrinol(Torino), 2024, 49(1):69-75. |
| [11] | CRAYTON H, WU K, LEONG D, et al. Diffuse sclerosing variant papillary thyroid carcinoma has worse survival than classic papillary thyroid carcinoma:a meta-analysis[J]. Endocr Relat Cancer, 2023, 30(6):e220348. |
| [12] | DU J, YANG Q, SUN Y, et al. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma:a retrospective study[J]. Front Endocrinol(Lausanne), 2023,14:1288527. |
| [13] |
MOROVAT P, MOROVAT S, HOSSEINPOUR M, et al. Survival-based bioinformatics analysis to identify hub long non-coding RNAs along with lncRNA-miRNA-mRNA network for potential diagnosis/prognosis of thyroid cancer[J]. J Cell Commun Signal, 2023, 17(3):639-655.
DOI |
| [14] |
RODRIGUES L, DA CRUZ PAULA A, SOARES P, et al. Unraveling the significance of DGCR8 and miRNAs in thyroid carcinoma[J]. Cells, 2024, 13(7):561-568.
DOI URL |
| [15] | RICCI C, SALVEMINI A, DALMIGLIO C, et al. From circulating tumor cells to mirna:new challenges in the diagnosis and prognosis of medullary thyroid cancer[J]. Cancers(Basel), 2023, 15(15):4009. |
| [16] |
CHEN W, HE Q, LIU J, et al. PLAGL2 promotes Snail expression and gastric cancer progression via UCA1/miR-145-5p/YTHDF1 axis[J]. Carcinogenesis, 2023, 44(4):328-340.
DOI URL |
| [17] | 兰天, 刘巍梦, 邹阳, 等. miR-145-5p靶向TPM3通过ERK信号通路抑制甲状腺癌TPC-1细胞侵袭和转移[J]. 中国医药生物技术, 2021, 16(1):18-26. |
| [18] |
GARRIDO-CANO I, ADAM-ARTIGUES A, LAMEIRINHAS A, et al. Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy[J]. ACS Appl Mater Interfaces, 2023, 15(32):38323-38334.
DOI URL |
| [19] | GUO K, WANG J, SHU L, et al. MiR-200c promotes papillary thyroid cancer cell proliferation,migration,and invasion by downregulating PTEN[J]. Tissue Cell, 2021,73:101647. |
| [20] |
GUZ M, JELENIEWICZ W, CYBULSKI M. An insight into miR-1290:an oncogenic miRNA with diagnostic potential. Int J Mol Sci, 2022, 23(3):1234.
DOI URL |
| [21] |
KALHORI M R, SOLEIMANI M, AREFIAN E, et al. The potential role of miR-1290 in cancer progression,diagnosis,prognosis,and treatment:an oncomiR or onco-suppressor microRNA?[J]. J Cell Biochem, 2022, 123(3):506-531.
DOI URL |
| [1] | DAI Jingwen, YANG Shuo, WANG Chong, SUN Lin, GU Meixiu, XIAN Jingrong, PAN Baishen, WANG Beili, ZHANG Chunyan, GUO Wei. Role of preoperative mean corpuscular hemoglobin concentration for predicting postoperative recurrence in intrahepatic cholangiocarcinoma patients [J]. Laboratory Medicine, 2025, 40(4): 344-349. |
| [2] | ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176. |
| [3] | LIU Yi, SU Xiaoming, WANG Yuanyuan, JU Tao. Roles of serum L-Arg and IL-4 levels in predicting recurrent ischemic stroke in patients with symptomatic carotid artery stenosis [J]. Laboratory Medicine, 2024, 39(7): 634-639. |
| [4] | DING Jing, ZHANG Chunling, WANG Xiaorui, LI Huidan, WANG Hongling, LIU Weiling, LIN Lihui, LI Li. Laboratory diagnosis and prognostic factor analysis of core binding factor-related acute myeloid leukemia [J]. Laboratory Medicine, 2024, 39(7): 673-681. |
| [5] | GU Liangliang, WANG Jianfeng, QIAO Xin, ZHANG Baochao, FU Guohui. Correlation between serum LRG1 level and cognitive impairment and recurrence in patients with acute ischemic stroke [J]. Laboratory Medicine, 2024, 39(5): 443-448. |
| [6] | SONG Xiaolong, QIN Jinlü, YANG Ru, WEI Long, ZHOU Jianping. Application of serum TK1 in postoperative monitoring of thyroid papillary carcinoma patients [J]. Laboratory Medicine, 2024, 39(2): 155-160. |
| [7] | SHEN Zhan, BIAN Xiaobo, HUANG Ying, WANG Siyang, SHEN Tingting, ZHANG Xian, SONG Yunxiao, XIE Lianhong. Stroke recurrence prediction model based on machine learning algorithms using routine blood test [J]. Laboratory Medicine, 2024, 39(12): 1190-1195. |
| [8] | LIANG Liang, YANG Haiqing, LI Yashan, WANG Jian, MAN Baohua, TANG Haixian, ZHANG Xiaojun, HE Sai, YIN Yan. Clinical roles of miR-21,miR-222,miR-146b and miR-7 in diagnosis of papillary thyroid carcinoma [J]. Laboratory Medicine, 2024, 39(11): 1027-1034. |
| [9] | YAN An, GUAN Xuhuizi, YU Tian, MIAO Gang, ZHAO Yanyang. Identification of a new susceptibility gene variant EPB41L4A rs1455421289 in Chinese PTC patients by WES [J]. Laboratory Medicine, 2023, 38(11): 1009-1014. |
| [10] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609. |
| [11] | LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422. |
| [12] | ZHENG Yu, CHEN Jin. Correlation between serum follistatin and clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer [J]. Laboratory Medicine, 2022, 37(11): 1066-1070. |
| [13] | MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46. |
| [14] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
| [15] | JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence [J]. Laboratory Medicine, 2020, 35(3): 209-213. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||